menu
    • menu
    [{"orgOrder":0,"company":"Yichang Humanwell Pharmaceutical","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Rematazolam Besylate","moa":"GABAA receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"Yichang Humanwell Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yichang Humanwell Pharmaceutical \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Yichang Humanwell Pharmaceutical \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Yichang Humanwell Pharmaceutical","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase III","graph3":"Yichang Humanwell Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yichang Humanwell Pharmaceutical \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Yichang Humanwell Pharmaceutical \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Yichang Humanwell Pharmaceutical","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase III","graph3":"Yichang Humanwell Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yichang Humanwell Pharmaceutical \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Yichang Humanwell Pharmaceutical \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Yichang Humanwell Pharmaceutical","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Undisclosed","graph2":"Phase III","graph3":"Yichang Humanwell Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yichang Humanwell Pharmaceutical \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Yichang Humanwell Pharmaceutical \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Yichang Humanwell Pharmaceutical","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Remimazolam Besylate","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"Yichang Humanwell Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yichang Humanwell Pharmaceutical \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Yichang Humanwell Pharmaceutical \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Yichang Humanwell Pharmaceutical","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Hydromorphone Hydrochloride","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Yichang Humanwell Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yichang Humanwell Pharmaceutical \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Yichang Humanwell Pharmaceutical \/ Yichang Humanwell Pharmaceutical"},{"orgOrder":0,"company":"Yichang Humanwell Pharmaceutical","sponsor":"Yichang Humanwell Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"Yichang Humanwell Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yichang Humanwell Pharmaceutical \/ Yichang Humanwell Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Yichang Humanwell Pharmaceutical \/ Yichang Humanwell Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Yichang Humanwell Pharmaceutical

    Menu

    Yichang Humanwell Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Yichang Humanwell Pharmaceutical

                            China arrow
                            The MedTech Conference
                            Not Confirmed

                            Yichang Humanwell Pharmaceutical

                            China arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydromorphone Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Recipient : The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intravenous Hydromorphone for the Treatment of Acute Pain

                            Details : Hydromorphone is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Chest Pain.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 29, 2025

                            Lead Product(s) : Hydromorphone Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Yichang Humanwell Pharmaceutical

                            China arrow
                            The MedTech Conference
                            Not Confirmed

                            Yichang Humanwell Pharmaceutical

                            China arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II/ Phase III

                            Recipient : Wuhan Union Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Evaluation of the Effectiveness and Safety of Nalbuphine Hydrochloride Injection for Analgesia in ICU Pati...

                            Details : Nalbuphine HCl is a Controlled Substance drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Respiratory Insufficiency.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            January 21, 2025

                            Lead Product(s) : Nalbuphine Hydrochloride

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II/ Phase III

                            Recipient : Wuhan Union Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Yichang Humanwell Pharmaceutical

                            China arrow
                            The MedTech Conference
                            Not Confirmed

                            Yichang Humanwell Pharmaceutical

                            China arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remimazolam Besylate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Recipient : Wuhan Union Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PK/PD Properties and Safety of Remazolam Besylate for Injection in ICU Patients With Impaired Renal Function

                            Details : Remimazolam Besylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 01, 2023

                            Lead Product(s) : Remimazolam Besylate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Recipient : Wuhan Union Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Yichang Humanwell Pharmaceutical

                            China arrow
                            The MedTech Conference
                            Not Confirmed

                            Yichang Humanwell Pharmaceutical

                            China arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remimazolam Besylate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Recipient : Wuhan Union Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Step 1 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in IC...

                            Details : Remimazolam Besylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 09, 2023

                            Lead Product(s) : Remimazolam Besylate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Recipient : Wuhan Union Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Yichang Humanwell Pharmaceutical

                            China arrow
                            The MedTech Conference
                            Not Confirmed

                            Yichang Humanwell Pharmaceutical

                            China arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remimazolam Besylate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase III

                            Recipient : Wuhan Union Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Step 2 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in IC...

                            Details : Remimazolam Besylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 24, 2023

                            Lead Product(s) : Remimazolam Besylate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase III

                            Recipient : Wuhan Union Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Yichang Humanwell Pharmaceutical

                            China arrow
                            The MedTech Conference
                            Not Confirmed

                            Yichang Humanwell Pharmaceutical

                            China arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rematazolam Besylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Recipient : Second Affiliated Hospital, Nanchang University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Rematazolam Besylate, Propofol, and Sevoflurane Perioperative Sedation on Incidence of Emergence Agi...

                            Details : Rematazolam Besylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Emergence Delirium.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 22, 2022

                            Lead Product(s) : Rematazolam Besylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Recipient : Second Affiliated Hospital, Nanchang University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Yichang Humanwell Pharmaceutical

                            China arrow
                            The MedTech Conference
                            Not Confirmed

                            Yichang Humanwell Pharmaceutical

                            China arrow
                            The MedTech Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remimazolam Besylate

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : Peking Union Medical College Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Availability and Safety Study of Remimazolam Besylate for Injection on Sedation of ERAS Patients

                            Details : Remimazolam Besylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Analgesia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 01, 2021

                            Lead Product(s) : Remimazolam Besylate

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : Peking Union Medical College Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth